Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1691 to 1700 of 2529

TitleReference numberPublishedLast updated
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancerTA939
Pembrolizumab with axitinib for untreated advanced renal cell carcinomaTA650
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancerTA770
Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancerTA1092
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1017
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)TA966
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancerTA904
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancerTA683
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal)TA1125
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinomaTA997

Results per page

  1. 10
  2. 25
  3. 50
  4. All